{"schema_version":"1.0","type":"article","title":"Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head","url":"https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.md","lang":"en","date":"2026-06-24","publish_at":"2026-06-24T08:13:00+08:00","updated_at":"2026-06-24","category":"商業分析系列","topic":"商業分析系列","tags":["AI drug discovery","zasocitinib","Takeda","Sotyktu","TYK2","psoriasis","PASI 100","Schrodinger","biotech investing","Big Pharma"],"summary":"Takeda's zasocitinib beat Sotyktu in a head-to-head Phase 3 psoriasis study, turning AI-enabled drug design into a real commercial test.","key_points":[],"facts":[],"sections":["1. In psoriasis, the bar has moved higher","2. Why zasocitinib matters for AI drug discovery","3. TYK2 is the narrow gate after JAK risk","4. Sotyktu teaches an important commercial lesson","5. Biologics remain a high wall","6. The oral psoriasis race is becoming more serious","7. The market could extend beyond psoriasis","8. Taiwan angle","Bottom line","References"],"references":[{"title":"Takeda. Phase 3 data release for zasocitinib in psoriasis.","source":"","date":"","url":""},{"title":"Schrödinger. Zasocitinib / TAK-279 case materials.","source":"","date":"","url":""},{"title":"Bristol Myers Squibb. Sotyktu prescribing information.","source":"","date":"","url":""},{"title":"Reuters. Coverage of oral psoriasis drugs and the TYK2 competitive landscape.","source":"","date":"","url":""},{"title":"Takeda. Pipeline and inflammatory disease strategy materials.","source":"","date":"","url":""},{"title":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","source":"","date":"","url":""}],"images":[{"alt":"AI-designed drug enters a real clinical exam","url":"https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu-en/cover.png"},{"alt":"Psoriasis efficacy bar from PASI 75 to PASI 100","url":"https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu-en/figure-01.png"},{"alt":"AI design path from modeling to clinical asset","url":"https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu-en/figure-02.png"},{"alt":"TYK2 as a narrow immune signaling gate","url":"https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu-en/figure-03.png"},{"alt":"Commercial exam for oral psoriasis therapies","url":"https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-24）。Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head。https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-24-ai-zasocitinib-sotyktu.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}